Filing Flows › Roivant Sciences (ROIV) › Q3 FY26
Roivant Sciences (ROIV) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Feb 6, 2026
Roivant Sciences (ROIV) reported revenue of $2.0M for the third quarter fiscal 2026 (Q3 FY26), -78% from a year earlier and +27% from the quarter before.
Roivant Sciences, Q3 FY26: revenue $2.0M (-78% year over year), net loss $314M, operating cash flow −$196M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.0M | +27% | -78% |
| Operating profit | −$339M | — | — |
| Net earnings | −$314M | — | -366% |
| Operating cash flow | −$196M | — | — |
What changed
Revenue was $2.0M in Q3 FY26, down 78% year over year and up 27% from the previous quarter.
Operating costs exceeded revenue by $339.2M, an operating margin of -16966.1%. Total costs grew 20% against a revenue fall of 78%. The fastest-growing cost line was General & admin (+24%). The quarter ended with a net loss of $313.7M, wider than the previous quarter's $166.0M loss. Minority interests bore $47.8M of it: to shareholders the quarter was a loss of $265.9M.
Operating cash flow was −$196.5M. Non-cash charges added back $691K of depreciation and amortization and $105.0M of share-based compensation. Working capital and other items added $11.5M. Capital expenditures of −$4.9M exceeded it, leaving free cash flow of −$191.5M.
Questions
What was Roivant Sciences' revenue in the third quarter fiscal 2026?
Roivant Sciences (ROIV) reported revenue of $2.0M for the third quarter fiscal 2026 (Q3 FY26), -78% from a year earlier and +27% from the quarter before.
Source: Roivant Sciences 10-Q on SEC EDGAR.